If Wave Life Sciences’ recently submitted trial application for WVE-006 is approved, it will become the first RNA editing treatment in a clinical development setting.
Wave’s CEO, Paul Bolno, explained to BioSpace that the process involves repairing a broken protein, restoring it to functional levels. Additionally, RNA editing is reversible, making it safer since the genetic code is not permanently altered.
However, with any ‘first’ in human tests, there will be a close watch for safety indications.
Unlike DNA editing, WVE-006 does not disturb areas surrounding the target site. As a result, the WVE-006 trial allows the participation of healthy volunteers.
If WVE-006 is approved, Wave anticipates enrolling the first participants within several months.
Several biopharma companies, including GSK, the British multinational company partnered with Wave on WVE-006, have shown interest in RNA editing.
One of GSK’s scientific officers commented that he had never witnessed such advances or incredible possibilities in this field.
CEO Bolno indicated that Wave intends to responsibly work with the first program they believe will revolutionize current therapy.
